Research Reports | Market Assessment
July 2017

Psoriatic Arthritis | Treatment Algorithms: Claims Data Analysis | US | 2017

The algorithms for treating psoriatic arthritis ( PsA ) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same therapies that are frequently used for PsA . Therefore, biologic and targeted synthetic DMARD s are more frequently used as early-line therapies after the diagnosis of PsA . Understanding the use of non- TNF inhibitors, namely, IL -12/23 inhibitors, IL -17 inhibitors, and PDE -4 inhibitors, is crucial for pharmaceutical companies to properly manage their brands in the PsA market. Claims data analysis provides an objective lens to see how physicians prescribe therapies and reveals real-world data on persistency and compliance of the PsA therapies.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports